Hutchmed announces licensing agreement with GSK for cancer therapy
HUTCHMED (China) Ltd (HKEX:13) said it has announced a licensing agreement with GSK for a Kras-EGFR-antibody conjugate cancer therapy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Hutchmed announces licensing agreement with GSK for KRAS-EGFR therapy
Hutchmed said it has announced a licensing agreement with GSK for a KRAS-EGFR antibody conjugate cancer therapy.